Specify a stock or a cryptocurrency in the search bar to get a summary
Biomx Inc
PHGEBiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. Address: 22 Einstein Street, Ness Ziona, Israel, 7414003
Analytics
WallStreet Target Price
16 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PHGE
Dividend Analytics PHGE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PHGE
Stock Valuation PHGE
Financials PHGE
Results | 2019 | Dynamics |